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Hypothyroidism and thyrotoxicosis are each associated with an
increased risk of fracture. Although thyroxine (T4) is the predom-
inant circulating thyroid hormone, target cell responses are deter-
minedby local intracellular availability of the active hormone 3,5,3′-
L-triiodothyronine (T3), which is generated from T4 by the type 2
deiodinase enzyme (D2). To investigate the role of locally produced
T3 in bone, we characterized mice deficient in D2 (D2KO) in which
the serum T3 level is normal. Bones from adult D2KO mice have
reduced toughness and are brittle, displaying an increased suscept-
ibility to fracture. This phenotype is characterized by a 50% reduc-
tion in bone formation and a generalized increase in skeletal
mineralization resulting from a local deficiency of T3 in osteoblasts.
These data reveal an essential role for D2 in osteoblasts in the opti-
mization of bone strength and mineralization.
thyroid hormone metabolism | fracture | hypothyroidism | bone
formation | skeleton
Thyroid hormones are essential for linear growth and peak bonemass acquisition. In adults, thyrotoxicosis results in high bone
turnover osteoporosis and increased susceptibility to fracture,
whereas hypothyroidism reduces bone turnover (1–3). In previous
studies, we identified thyroid hormone receptor α (TRα) as the
critical mediator of 3,5,3′-L-triiodothyronine (T3) action in bone
(4–7). The aim of this study is to investigate the role of the type 2
iodothyronine deiodinase (D2) as a local prereceptor modulator
of T3 action in the skeleton.
Thyroid hormone actions are determined by local availability of
T3 to its nuclear receptor (8). D2 catalyzes removal of an outer
ring 5′-iodine atom from the major circulating hormone thyroxine
(T4) to generate the active metabolite T3. Conversely, the type 3
deiodinase (D3) inactivates both T4 and T3 by removal of an
inner ring 5-iodine atom. Thus, D2 and D3, in conjunction with
serum-derived T3, are important local modulators of thyroid
hormone action in vivo. Expression of D2 and D3 is regulated in a
temporo-spatial and tissue-specific manner, resulting in varying
levels of T3 action in individual tissues despite relatively constant
serum thyroid hormone levels (8).
Mice deficient in D2 (D2KO) exhibit pituitary resistance to
feedback regulation by T4 characterized by a 3-fold increase in
serum thyroid-stimulating hormone (TSH), a 27% increase in the
serum T4 level, but a normal T3 level. The increased TSH and T4
levels are evident as early as postnatal day (PD)10 (9). These
changes are accompanied by cold intolerance, impaired hearing,
and reduced brain T3 content (10). The type 1 deiodinase (D1) is
widely believed to catalyze conversion of T4 to T3 in tissues such
as liver and kidney, predominantly for export to plasma. Like the
D2KO mice, D1/D2KO double-mutant mice exhibit increases in
serum T4 and TSH and have a normal serum T3 level (10).
The roles of D1 and D2 in regulating T3 action in the skeleton
have not been studied, although limited information regarding
growth is available. A minor and transient impairment of weight
gain was reported in male D2KO mice, whereas weight gain and
growth were normal in D1KO and D1-deficient C3H/HeJ mice
and inC3H/HeJD2KOmutantswithD1andD2deficiency (11–15).
We and others have shown that D1 is not expressed in skeletal cells
(16–19), indicatingD1doesnot influenceT3action in bone directly.
D2 activity has been demonstrated in the embryonic growth plate
where it is regulated by the skeletal morphogen Hedgehog (20).
Nevertheless, D2 activity was not identified in primary chon-
drocytes, growth plate tissue extracts, or primary organ cultures
frompostnatal animals (19, 21–23), suggesting a discrete role during
embryonic development. In osteoblasts data are conflicting (16, 18,
24), although specific D2 activity was identified in whole bone and
differentiated MC3T3 osteoblastic cells in one study (17). Using a
sensitive and highly specific HPLC-based assay, we showed D2
is restricted to mature primary osteoblasts but is undetectable in
chondrocytes andosteoclasts (19).Wehypothesized, therefore, that
D2KOandD1/D2KOmice would display equivalent abnormalities
of bone turnover andmineralization reflecting the restricted activity
of D2 in mature osteoblasts and the absence of D1 from bone.
Results
D2KO Mice Have Brittle Bones. The strength and biomechanical
characteristics of bone from adult D2KOandD1/D2KOmice were
investigated by destructive three-point bend testing (Fig. 1A andB).
Analysis of load displacement curves revealed the extrinsic rigidity
(stiffness), intrinsic stiffness (Young’smodulus), and biomechanical
parameters ofWTandmutantbones tobe similar (Fig. 1BandC i-ii,
Fig. S1, and Table S1). The major difference in mutant femurs was
their behavior following maximum load. WT specimens showed
considerable work softening, demonstrated by a 35% fall in applied
load from 18.4 ± 0.8 N to 12.2 ± 1.2 N, whereas displacement
continued to 0.43±0.03mmbefore fracture occurred (Fig. 1C iii–iv,
Fig. S1, and Table S1). By contrast, mutant femurs sustained a
sudden fracture almost immediately after maximum load (Fig. S1).
Thus, femurs from mutant mice behave as a classic brittle material
that fails in a single abrupt fracture. WT femurs, however, sustain
nonpropagatingmicrofractures that absorb energy but do not result
in failure until considerable internal microdamage has occurred.
Themajor benefits of these nonpropagatingmicrofractures are that
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the bone can survive marked deformation beyond maximum load
and significant elastic stored-strain energy is dissipated before
fracture. Thus, only a small amount of stored energy remains atfinal
fracture, resulting in less widespread damage. The elastic stored-
strain energy at maximum load and fracture is illustrated in Fig. S1.
At maximum load, values in bones of both WT and mutant mice
were similar, but at fracture the value in WT femurs had fallen by
79%, the remaining stored energy being only 1.0 Nmm compared
with 2.5 Nmm in D2KOmice (Fig. 1Cv, Table S1, Fig. S1). Indeed,
the mutant femurs dissipated only 21–46% of their energy before
fracture (Table S1). Thus, WT bones display work-softening duc-
tility, whereas femurs from D2KO mice are brittle, have reduced
toughness, and sustain destructive fractures (Fig. 1Cvi, Table S1).
High Bone Mineral Density and Osteoblast-Specific Hypothyroidism in
D2KOMice.Todeterminewhether brittlebones inD2KOmice result
from abnormal mineralization, bone mineral density was measured
by Faxitron point projection digital microradiographic analysis and
quantitative backscattered electron scanning electron microscopy
(qBSE-SEM). Relative and cumulative frequency histograms
obtained from Faxitron analysis of tibias revealed increased bone
mineral content inmutantmice (Fig. 2A andB). Detailed studies at
the cubic-micrometer volume resolution scalewereperformedusing
qBSE-SEM. Frequency histograms of bone micromineralization
densities fromcombinedcortical and trabecularbone sites (Fig.S2A
andB) or discrete regions of trabecular (Fig. 2C andD) and cortical
(Fig. 2 E and F) bone demonstrated high bone mineralization in
mutants. Further studies were performed to determine whether
these findings were recapitulated by manipulation of systemic thy-
roid status in WT mice. A similar increase in bone mineral content
was observed in hypothyroid mice, whereas bone mineral content
was reduced in thyrotoxic animals (Fig. S3). Thus, in addition to
brittle bones, adultD2KOmice have increased bonemineralization
consistent with tissue hypothyroidism in bone, despite a normal
circulating level of T3. To investigate further, in situ hybridization
Fig. 1. Mechanical properties of bone in D2KO and D1/D2KO mice. (A)
Faxitron image of fractured femur following a three-point bend test. The site
of fracture and region for measurement of diameter and cortical thickness
are shown. (B) Load–displacement curves ofWT and D2KO femurs. The points
of yield load, maximum load, and fracture load and the gradient of the linear
elastic phase, representing the extrinsic rigidity or stiffness of the bone, are
shown. (C) Graphs showing (i) yield load, (ii) maximum load, (iii) fracture
load, (iv) displacement at fracture, (v) elastic stored-strain energy at fracture,
and (vi) toughness of WT, D2KO, and D1/D2KO femurs. ANOVA and Tukey’s
post hoc test; *, P < 0.05, **, P < 0.01 versus WT (n = 5–7).
Fig. 2. Bone micromineralization density in D2KO and D1/D2KO mice. (A)
Faxitron images of tibias from PD112 WT, D2KO, and D1/D2KO mice. Gray-
scale images were pseudocolored according to a 16-color palette; low min-
eralization density is black, high density is white. (Scale bar, 1 mm.) (B)
Relative (RF) and cumulative frequency (CF) histograms of mineralization
densities from whole tibia. Kolmogorov-Smirnov test; **, P < 0.01; ***, P <
0.001 versus WT (n = 5–6). (C) qBSE-SEM images of metaphyseal trabecular
bone from PD112 WT, D2KO, and D1/D2KO mice. (Scale bar, 200 μm.) Gray-
scale images were pseudocolored according to an eight-color palette; low
mineralization density is blue, high density is gray. Regions of trabecular
bone correspond to boxed areas in Fig. S2A. (Scale bar, 200 μm.) (D) RF and
CF histograms of trabecular bone micromineralization densities from femur,
tibia, and humerus. Kolmogorov-Smirnov test; ***, P < 0.001 versus WT (n =
4). (E) qBSE-SEM images of midshaft humerus cortical bone. (F) RF and CF
histograms of cortical bone micromineralization densities from femur, tibia,
and humerus. Kolmogorov-Smirnov test; ***, P < 0.001 versus WT (n = 4).







was performed to determine expression of the T3-target gene Fgfr1
in bone. These studies revealed an osteoblast-specific reduction in
Fgfr1 expression in mutant mice, indicating the presence of restric-
ted cellular hypothyroidism in osteoblasts (Fig. S4).
Normal Bone Development in D2KO Mice. Skeletal development was
analyzed to determine whether this phenotype results from
abnormal bone formation and growth. There were no differences
in skeletal elements between mutant and WT mice at PD1. Bone
formation and growth did not differ between PD14 and PD112,
and treatment ofWTandD2KOmice with T3 had no effect (Fig. 3
and Fig. S5). Histological analysis of the tibia revealed a 20%
reduction in total growth plate height in PD21 D1/D2KO mice
compared withWT, but no differences were found in D2KOmice
or mice treated with T3 (Fig. 3 D–F). The reduced growth plate
height in D1/D2KO mice resulted from narrower reserve (RZ)
and hypertrophic (HZ) zones, and small reductions in the heights
of the proliferative zone (PZ) andHZwere evident inD2KOmice.
Nevertheless, the relative sizes of theRZ, PZ, andHZwere similar
in all genotypes, and growth plate parameters did not differ in
PD56 and PD112 mice, indicating that any difference was minor
and transient. Importantly, the differences were not accompanied
by altered linear growth or bone formation and are thus of no
biological significance. Similarly, cortical bone thickness did not
differ in mutant or T3-treated mice (Fig. 3G and Fig. S5C andD).
The normal endochondral ossification inD2KOmice is consistent
with the absence of D2 activity in growth plate chondrocytes (19),
and the adult brittle bone phenotype therefore is not a con-
sequence of abnormal skeletal development.
Normal Bone Microarchitecture but Reduced Bone Volume in D2KO
Mice. To determine whether brittle bones and increased minerali-
zation were accompanied by structural changes of the adult skeleton,
bone microarchitecture was analyzed by BSE-SEM. Low-power
viewsofdistal femur (Fig. 4A) revealednodifferences in corticalbone
thickness and trabecular bone structure between mutant and WT
mice. In-high power views (Fig. 4B), the thickness and connectivity
of individual trabeculae were similar also. Thus, adult mutant mice
have normal bonemicroarchitecture. The bone volumes of vertebrae
and long bones (BV/TV) were determined by qBSE-SEM and high-
Fig. 3. Bone development and growth in D2KO and D1/D2KO mice. (A)
Limbs and skull from PD1 WT and D2KO mice stained with Alcian blue
(cartilage) and alizarin red (bone). (B) Tibias from PD21 WT, WT+T3-treated,
D2KO, D2KO+T3-treated, and D1/D2KO mice. (C) Growth curves between
birth and PD112. (n = 4–14). (D) Proximal tibia growth plates stained with
Alcian blue and van Gieson (osteoid) (magnification ×50 and ×200). E, epi-
physis; GP, growth plate; HZ, hypertrophic zone; PZ, proliferative zone; RZ,
reserve zone. (E) Growth plate and chondrocyte zone heights in PD21 mice.
Growth plate zone measurements (Left) and proportions relative to height
of the growth plate (Right). ANOVA and Tukey’s post hoc test, D2KO and D1/
D2KO versus WT: *, P < 0.05; **, P < 0.01 comparison of growth plate zones;
##, P < 0.01 comparison of growth plate heights (n = 4–8). (F) Changes in
growth plate heights between PD14 and PD112. Student’s t test: *, P < 0.05
D2KO versus WT; ##, P < 0.01 D1/D2KO versus WT (n = 3–8). (G) Changes in
femur cortical bone thickness (CT) between PD14 and PD112 (n = 3–5).
Fig. 4. Bone microarchitecture in D2KO and D1/D2KO mice. (A and B) BSE-
SEM views of distal femur from PD112 WT, D2KO, and D1/D2KO mice. (Scale
bars, 200 μm.) (C and D) Sections of proximal humerus and caudal vertebra
from PD112 WT, D2KO, and D1/D2KO mice imaged by qBSE SEM. (Scale bars,
200 μm.) (E) Quantitative analysis of bone volume (BV/TV) in PD112 mice.
ANOVA and Tukey’s post hoc test. *, P < 0.05; **, P < 0.01 versus WT (n = 4).
(F) Trabecular bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular
spacing (Tb.Sp), trabecular number (Tb.N), and structure model index (SMI)
determined by micro-CT analysis of proximal tibia from PD112 D1/D2KO and
WT mice (n = 5).
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resolution micro-CT (Fig. 4 C–F). Vertebral bone volume was
reduced by 20% in D2KO mice (P < 0.01) and by 9% in D1/D2KO
mice (P < 0.05), whereas long bone parameters were similar.
Normal Bone Resorption in D2KO Mice. To investigate whether
altered bone resorption accounts for the brittle bone phenotype,
the numbers of osteoclasts (Oc.N), osteoclast surfaces (Oc.S), and
total bone surfaces (BS) were quantified (Fig. 5 A and B). There
were no differences in Oc.N/BS or Oc.S/BS in mutant mice, indi-
cating that osteoclast numbers and resorption were normal. To
investigate further, areas of scalloped osteoclast bone resorption
on endosteal and trabecular bone surfaces were quantified by
BSE-SEM (Fig. 5C–E). There was no difference in the resorption
surface relative to total bone surface, confirming that bone
resorption is normal in mutant mice. Accordingly, there were no
differences in the serum bone resorption markers C-terminal
crosslinked telopeptide of type I collagen (CTX) and tartrate-
resistant acid phosphatase form 5b (TRAP) (Fig. S6). Thus, the
phenotype is not a consequence of altered bone resorption.
Reduced Bone Formation in D2KO Mice. To investigate whether
altered osteoblastic bone formation accounts for the phenotype,
mineralizing surfaces, BS, mineral apposition rates (MAR), and
bone formation rates (BFR) were quantified in calcein double-
labeled adult mice (Fig. 6 A–D). In mutants mineralizing surfaces
were reduced by 25–35% in trabecular bone and 45–46% in cal-
varia,whereasMARwas reducedby 17–28% in trabecular bone and
24–36% in calvaria. Consequently, BFR was reduced by 37–52% in
trabecular bone and by 58–72% in calvaria. Histomorphometric
analysis of trabecular osteoblast function was performed also (Fig. 6
E and F). Osteoblast surfaces (Ob.S) and number (Ob.N) and
osteoid surfaces (OS) and width (O.Wi) were quantified. Ob.S/BS
was reduced by 43–56% in mutant mice, whereas Ob.N/Ob.S was
increasedby29–38%.Consequently, the totalnumberofosteoblasts
(Ob.N/BS) did not differ between WT and mutant mice, although
mutant osteoblasts were smaller (Fig. 6F). Osteoid surface per mm
of osteoblast surface (OS/Ob.S) also was similar in all animals, but
O.Wi was reduced by 39–49% in mutants. Although the BFR was
decreased inmutant mice, serum bone formationmarkers were not
reduced at PD91, reflecting the low levels of bone turnovermarkers
observed at this age and the greater sensitivity of dynamic histo-
morphometry (Fig. S6). Thus, the brittle bone phenotype in D2KO
mice results from reduced osteoblast activity.
Fig. 5. Bone resorption in D2KO and D1/D2KO mice. (A) TRAP-stained sec-
tions from PD112 WT, D2KO, and D1/D2KO mice. (Scale bar, 100 μm.) (B)
Quantitative analysis of osteoclast surface (Oc.S) and the number of TRAP-
positive osteoclasts (Oc.N) relative to bone surface (BS). ANOVA (n = 3–4). (C)
Trabecular bone surfaces from PD112 WT, D2KO, and D1/D2KO mice imaged
by BSE-SEM. White arrows indicate roughened osteoclast resorption surfa-
ces. (Scale bar, 200 μm.) (D) Endosteal surfaces from PD112 mice. Black
arrows indicate junctions between roughened resorption surfaces and
smooth unresorbed bone. (Scale bar, 200 μm.) (E) Quantitative analysis of
osteoclast resorption surfaces (% of total bone surface). ANOVA (n = 3–5).
Fig. 6. Bone formation in D2KO and D1/D2KO mice. (A) CSLM views of
trabecular bone. (Scale bar, 10 μm.) (B) Trabecular bone mineralizing surface
(MS), mineral apposition rate (MAR), and bone formation rate (BFR) deter-
mined by dual calcein labeling. ANOVA and Tukey’s post hoc test; *, P < 0.05;
**, P < 0.05 versus WT (n = 4). (C) CSLM views of calvarial bone. (Scale bar, 10
μm.) (D) Quantitative analysis of intramembranous bone deposition in cal-
varia. *, P < 0.05 versus WT; **, P < 0.05 versus WT (n = 3–4). (E) Toluidine
blue-stained osteoblasts from PD112 WT, D2KO, and D1/D2KO mice. (Scale
bar, 10 μm.) (F) Histomorphometry analysis of osteoblast parameters. *, P <
0.05 versus WT; **, P < 0.05 versus WT (n = 4).








We demonstrate that D2KO mice, which lack D2 that regulates
intracellular T3 availability, have brittle bones of increased
mineralization and reduced bone formation because of restricted
cellular hypothyroidism in osteoblasts. These data provide fun-
damental insight into thyroid hormone action in bone, revealing
an essential role for D2 in optimizing toughness and minerali-
zation of the skeleton.
D2 Is Essential for Normal Osteoblast Function. Studies of the skel-
etal consequences of hypothyroidism in humans demonstrated
low bone turnover and a prolonged bone remodeling cycle with
impaired osteoclast and osteoblast function (25–27). Osteoclast
activity and bone resorption surfaces were reduced, and osteo-
blast activity and osteoid apposition were impaired. The bone
formation phase in each remodeling cycle was prolonged 4-fold,
resulting in an extended period of secondary mineralization (25–
27). In the current studies, D2KO mice similarly had low bone
turnover and impaired osteoblast activity with reduced mineral-
ized surfaces and BFR. Osteoclast function was unaffected,
indicating D2KO mice have an osteoblast-specific defect that
results from intracellular T3 deficiency despite the presence of a
normal circulating concentration of T3. This phenotype is con-
sistent with restricted expression Dio2 in osteoblasts and its
absence from osteoclasts (19). D1/D2KO mice exhibited a phe-
notype comparable with D2KOmice, reflecting the absence of D1
activity in bone (16–19). Thus, reduced toughness and resistance
to fracture in D2KO and D1/D2KO mice reveals an important
role for D2 in osteoblasts in the optimization of bone strength.
Mouse Models of Skeletal Hypo- and Hyperthyroidism. Recent stud-
ies in congenitally hypothyroid TSH receptor-null mice have pro-
posed TSH as a regulator of bone turnover acting directly in
osteoblasts and osteoclasts (28). Further in vivo studies demon-
strated increased bone formation and reduced bone resorption in
rats and mice treated with doses of TSH that were insufficient to
affect circulating thyroid hormone levels (29). The current find-
ings, however, are inconsistent with these observations, because
D2KO and D1/D2KO mice exhibit impaired rather than inc-
reased bone formation and normal rather than reduced bone
resorption despite a 3-fold elevation of the serum TSH level and
a normal serum T3 concentration. Thus, the role of TSH in bone
remains uncertain (30).
By contrast, the importance of D2 activity in osteoblasts is sup-
ported by the skeletal phenotypes of thyroid receptor (TR)-mutant
mice. TRα1R384C/+mice, which express a dominant negative TRα1
protein, have skeletal hypothyroidism because of impaired TRα1
signaling in bone that results in increased bonemineralization and
an additional reduction in osteoclast activity (4). TRβ−/−mice have
central thyroid hormone resistance, elevated serum thyroid hor-
mone levels, and skeletal hyperthyroidism caused by increased
activation of TRα1, the predominant TR isoform in bone.
Accordingly, this skeletal hyperthyroidism results in reduced bone
mineralization and increased osteoclast activity (4, 5). Together,
these data indicate that defective TRα1 signaling inhibits osteo-
blast and osteoclast activities, whereas increased activation of
TRα1 stimulates both osteoblasts and osteoclasts. In D2KO and
D1/D2KO mice, however, the cellular defect is different, because
D2 activity normally is present only in osteoblasts. D2KO and D1/
D2KO mutants lack intracellular D2-mediated T4 to T3 con-
version but have a normal circulating T3 concentration. Thus,
cellular hypothyroidism in bone is restricted to osteoblasts and
consequently ismanifest by reduced bone formation and increased
mineralization without an accompanying defect of osteoclast
function. The normal physiological activity of TRα1 in osteoblasts
therefore requires an adequate intracellular level of T3 that is
dependent, at least in part, on D2. By contrast, thyroid hormones
and TRα1 also exert D2-independent actions in osteoclasts.
Thyroid status, therefore, influences the activities of both
osteoclasts and osteoblasts. Thyrotoxicosis increases osteoblast
and osteoclast activities, resulting in high bone turnover osteo-
porosis (2), whereas hypothyroidism results in low bone turnover
with reduced osteoblast and osteoclast activities and a net increase
in bone mineralization (25–27). Surprisingly, large population
studies demonstrate that both conditions are associated with an
increased susceptibility to fracture (3, 31, 32).
D2 Has an Essential Physiological Role in Bone. The current study
identifies a critical function for D2 in osteoblasts that may account
for this unexpected observation. The findings suggest a model in
which restricted expression of D2 maintains a higher intracellular
T3 concentration in osteoblasts relative to other skeletal cells that
is essential for their normal function (Fig. 7A). An analogous role
for D2 has been described previously in the developing cochlea
(33). As in other tissues, D2 activity in osteoblasts is up-regulated
in hypothyroidism and down-regulated in hyperthyroidism (17).
Thus, D2 acts as a local homeostatic regulator that buffers the
detrimental effects of altered serum thyroid hormone levels on the
skeleton.Wepropose that adverse effects of T3 deficiency on bone
mineralization are mitigated by increased D2-mediated con-
version of T4 to T3 in osteoblasts, whereas inhibition of osteo-
blastic D2 activity limits the detrimental effects of thyroid hor-
mone excess. Nevertheless, the capacity of this local feedback
mechanism in osteoblasts is insufficient to compensate in overt
hypothyroidism or thyrotoxicosis (Fig. S3). Thus, we hypothesize
that optimal bone mineral content and resistance to fracture are
maintained over the physiological range of systemic thyroid hor-
mone concentrations by the regulated activity of D2 in osteoblasts
(Fig. 7B). Absence of this compensatory mechanism in D2KO
mice results in cellular hypothyroidism and brittle bones. These
Fig. 7. Proposed physiological role for D2 in bone. (A) Thyroid status regu-
lates osteoclasts (OC) and osteoblasts (OB). Hypothyroidism reduces bone
turnover and thyrotoxicosis increases bone turnover, but both conditions
increase fracture risk. In osteoblasts, D2 is up-regulated in hypothyroidism but
is reduced in hyperthyroidism. We propose that increased D2-mediated con-
version of T4 to T3 in osteoblasts mitigates adverse effects of T3 deficiency on
bone mineralization, whereas reduced osteoblastic D2 activity limits the det-
rimental effects of thyroid hormone excess. (B) Role of D2 in the relationship
between bone mineralization and fracture risk. Regulated D2 activity in
osteoblasts maintains optimal bone mineralization within the euthyroid
range. Absence of this local feedback mechanism in D2KO mice results in
cellular hypothyroidism despite circulating euthyroidism, an isolated reduc-
tion in osteoblast activity, and brittle bones. The system, however, has insuf-
ficient capacity to compensate in overt hypothyroidism and thyrotoxicosis,
resulting in increased susceptibility to fracture in both conditions.
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studies identify D2 as a possible therapeutic target to manipulate
bone strength.
Materials and Methods
D2KO and D1/D2KO Mice. Homozygous colonies of WT, D2KO, and D1KOmice
were housed at Dartmouth Medical School animal facility using protocols
approved by the Institutional Review Board. Some PD21 mice were rendered
hyperthyroid by adding T3 (0.3 μg/mL) to the drinking water of nursing
mothers (SI Materials and Methods).
Faxitron Imaging. Digital x-ray images of long bones and tail vertebrae at 10-
μm resolution were recorded using a Qados Faxitron MX20 variable kV point
projection x-ray source (Cross Technologies plc.) (SI Materials and Methods).
qBSE-SEM. Bone micromineralization densities were analyzed at cubic-
micrometer resolution by qBSE-SEM (SI Materials and Methods).
Mechanical Testing. Three-point bend tests were performed on femurs from
PD112 mice using an Instron 5543 load frame (Instron Limited) (SI Materials
and Methods).
Skeletal Preparations and Histology. PD1 mice and limbs from older animals
were stained with alizarin red and Alcian blue. Sections of decalcified bones
were stained with van Gieson and Alcian blue, and growth plate and cortical
bone dimensions were determined. Osteoclasts were analyzed in sections
stained for TRAP (SI Materials and Methods).
BSE-SEM. Long bones were fixed in 70% ethanol, opened longitudinally,
cleaned of cell remnants, and imaged by BSE-SEM (SI Materials andMethods).
Micro-CT Analysis. Tibia were fixed and stored in 70% ethanol and sub-
sequently imaged bymicroCT at a detection pixel size of 4.3 μm2. (SIMaterials
and Methods).
Measurement of Bone Turnover Markers. Serum markers of bone formation
and resorption were measured in samples from P91WT and D1D2KO mice (SI
Materials and Methods).
Confocal Microscopy. Midline longitudinal and midcoronal block faces were
cut through methacrylate-embedded long bones and calvaria. Specimens
were examined by confocal autofluorescence scanning light microscopy
(CSLM) to determine the fraction of bone surface undergoing active bone
formation (SI Materials and Methods).
Osteoblast Histomorphometry.Methacrylate embedded sections were stained
with toluidine blue, and primary histomorphometric indices of bone for-
mation were determined (SI Materials and Methods).
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